Alexion Pharma (ALXN) Tops Q4 EPS by 32c, FY EPS Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharmaceuticals (ALXN) PT Lowered to $165 at RBC Capital
February 5, 2019 6:42 AM ESTRBC Capital analyst Kennen MacKay lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $165.00 (from $170.00) while maintaining a Outperform rating.
MacKay commented, "We came away from ALXNs Q4:18 call excited by detail into a growing pipeline stable and increasing confidence that... More
